A–Z Peptide Catalogue

A small-molecule NNMT inhibitor used in preclinical metabolic research; it is not an approved medicine.

An investigational soluble activin receptor designed to alter myostatin and related signalling in muscle research.

A dilute acidic laboratory diluent. Suitability depends on the material and protocol; it is not interchangeable with every reconstitution solution.

The full-length corticotropin peptide, studied for its role in stimulating adrenal corticosteroid production.

A supplier catalogue name without a clearly established international non-proprietary identity; composition should be confirmed from a COA before research use.

An experimental peptide studied preclinically for effects on blood vessels associated with adipose tissue; it is not an approved treatment.

A copper-binding tripeptide investigated in laboratory models involving skin, hair follicles and extracellular-matrix biology.

An adenosine analogue used in laboratory research to activate AMPK and investigate cellular energy regulation.

A modified fragment of human growth hormone studied for metabolic signalling; it is not an approved weight-management medicine in the UK.

An investigational erythropoietin-derived peptide studied for tissue-protective and anti-inflammatory signalling without red-cell stimulation.

A single-chain relaxin-family peptide investigated preclinically for fibrosis and tissue-remodelling pathways.

Bacteriostatic water is sterile water containing a preservative. Laboratory use must follow the material specification and compatibility requirements.

An experimental peptide widely used in preclinical tissue-repair research; reliable human clinical evidence is limited and it is not an approved medicine.

A long-acting amylin analogue under clinical investigation for appetite and body-weight regulation.

An investigational combination of an amylin analogue and a GLP-1 receptor agonist studied in metabolic and weight-management trials.

A supplier catalogue label whose exact chemical identity is not established by the name alone; verify the formulation and analytical documentation before research use.

A catalogue name commonly used for modified GRF (1–29), a GHRH analogue without the drug-affinity-complex modification. Confirm its sequence; it is not simply the same molecule as CJC-1295 with DAC.

A research blend combining a GHRH analogue with a ghrelin-receptor agonist; the blend is not an approved medicine.

A longer-acting GHRH analogue incorporating a drug-affinity-complex modification, studied for growth-hormone signalling.

A potent opioid peptide originally identified in amphibian skin and used in receptor and analgesia research; it carries serious opioid-related risks.

An experimental small molecule derived from angiotensin-related research and studied preclinically for synaptic and neurotrophic pathways.

Delta sleep-inducing peptide is an experimental neuropeptide studied in sleep and stress research; its biological role remains uncertain.

A long-acting GLP-1 receptor agonist used as a prescription medicine for type 2 diabetes; catalogue information is for reference only.

A synthetic tetrapeptide explored in research on cellular ageing, oxidative stress and circadian biology. Evidence is limited and does not establish strong longevity claims or an approved anti-ageing use.

Protein identity and isoform require confirmation A protein that binds activins and related growth factors, used in research on muscle, reproduction and tissue regulation.

A transcription factor central to cell-cycle, stress-response and longevity research; the catalogue name alone does not define a particular peptide sequence.

An experimental D-retro-inverso peptide studied preclinically for interactions involving FOXO4 and senescent cells.

A follistatin isoform investigated for its binding to activin and myostatin-family proteins in muscle and developmental research.

Growth differentiation factor 8, also called myostatin, is a signalling protein studied for its role in limiting skeletal-muscle growth.

A naturally occurring copper-binding tripeptide researched in skin, extracellular-matrix and wound-repair biology. Studies explore collagen, elastin, tissue remodelling and hair-follicle pathways, with evidence varying by formulation and use.

A synthetic ghrelin-receptor agonist studied for growth-hormone release and endocrine signalling.

The acetate salt of GHRP-2, a synthetic ghrelin-receptor agonist used in experimental endocrine research.

A naturally occurring cellular antioxidant used in biochemical research on redox balance, detoxification and oxidative stress.

A synthetic form of gonadotropin-releasing hormone used to study pituitary LH and FSH release.

HCG means human chorionic gonadotrophin, a hormone used in specific licensed medical contexts. The vial strength is shown for catalogue identification only.

A synthetic growth-hormone secretagogue and ghrelin-receptor agonist studied in endocrine research.

Human growth hormone regulates growth and metabolism. It is a prescription-only biological medicine and should not be treated as a general research supplement.

A C-terminal growth-hormone fragment investigated for metabolic signalling; it is not an approved medicine.

HMG means human menopausal gonadotrophin, a prescription fertility hormone preparation. The vial strength is shown for catalogue identification only.

A mitochondria-associated peptide investigated in preclinical studies of cellular stress, metabolism and neuroprotection.

A modified, longer-acting analogue of insulin-like growth factor 1 used to investigate IGF-1 receptor signalling. Laboratory research considers cell growth, protein synthesis and metabolic pathways; it is a research reagent rather than an approved medicine.

A shortened IGF-1 analogue used in experimental studies of IGF-receptor signalling and tissue growth.

A selective ghrelin-receptor agonist studied for growth-hormone release; it is not an approved medicine.

A short active fragment of kisspeptin used to investigate hypothalamic control of reproductive hormone signalling.

A three-amino-acid fragment of alpha-MSH investigated for anti-inflammatory signalling. Laboratory and animal studies explore epithelial barriers, skin and gastrointestinal models; effects in people have not been established.

A naturally occurring compound involved in transporting fatty acids into mitochondria and widely studied in energy metabolism.

A supplier-defined lipotropic mixture; ingredients and concentrations vary, so the name alone is insufficient to establish composition.

A supplier-defined lipotropic mixture rather than a standardised drug name; verify every ingredient and concentration from the formulation record.

A non-standardised lipotropic mixture that includes vitamin B12; exact composition varies between suppliers.

A GLP-1 receptor agonist used as a prescription medicine for diabetes and weight management in approved products and indications.

A human antimicrobial peptide studied for innate immunity, inflammation and host-defence signalling.

A dual GLP-1 and glucagon receptor agonist studied in metabolic trials. Specific mazdutide medicines are authorised in China; that approval does not apply to a UK research-labelled catalogue item.

An analogue of alpha-MSH related to afamelanotide and studied for melanocortin signalling and pigmentation.

A pack of 50 oral tablets, each labelled to contain 5 mg of melatonin, the hormone N-acetyl-5-methoxytryptamine. This item is not an anabolic steroid.

Mechano growth factor is an IGF-1 splice-variant concept studied in muscle adaptation; commercial catalogue material may not match endogenous MGF.

Ibutamoren is an investigational small molecule, not a peptide, that activates the ghrelin receptor in growth-hormone and IGF-1 research.

A mitochondria-derived peptide studied as a signal connecting cellular stress, energy use and metabolic adaptation. Research explores mitochondrial function, insulin sensitivity and exercise-response pathways, although most intervention evidence remains preclinical.

Melanotan II (MT2) is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH), a signal involved in skin pigmentation. It activates melanocortin receptors and is studied for its ability to stimulate melanin, the pigment responsible for skin colour and tanning. A small early human study observed increased pigmentation, but this does not establish long-term safety or validate this pen formulation. Reported effects include nausea, flushing and changes in moles or freckles. This entry identifies the labelled 10 mg pen format. For research purposes only; not an approved tanning treatment or a substitute for sun protection.

NAD+ (nicotinamide adenine dinucleotide) is a cellular coenzyme involved in oxidation–reduction reactions and energy metabolism. It is not a peptide. The listed strength and presentation identify the catalogue format, not proven bioavailability or an established anti-ageing effect.

A neuropeptide involved in wakefulness, arousal and energy-balance signalling, used in neuroscience research.

The acetate salt of oxytocin, a peptide hormone involved in uterine, lactation and social-behaviour pathways.

An experimental spadin-derived peptide investigated preclinically for TREK-1 potassium-channel and neurobehavioural pathways.

A pegylated catalogue form associated with mechano growth factor research; identity and biological comparability require analytical verification.

A short synthetic peptide investigated in limited experimental work involving neural and cellular ageing pathways.

An experimental p53-derived peptide studied preclinically for interactions with cancer-cell membranes; it is not an approved cancer treatment.

Bremelanotide is a melanocortin-receptor agonist studied for sexual-function signalling; regulatory status and approved indications differ by country.

An investigational triple receptor agonist designed to act on GLP-1, GIP and glucagon pathways. Researchers are studying how this combined signalling may affect appetite, glucose regulation, energy balance and body composition. It is not currently an approved UK medicine.

A non-standard experimental mixture of two incretin-pathway compounds. It is not an approved formulation and its composition requires independent verification.

A synthetic tuftsin-derived peptide studied in anxiety, stress, cognition and neuroimmune signalling models. The evidence base remains limited and does not establish guaranteed mood or cognitive effects.

A GLP-1 receptor agonist used in authorised prescription medicines for diabetes and weight management; unlicensed material is not equivalent to an approved product.

A synthetic ACTH-derived peptide investigated in neurological, cognitive and stress-response research. Published work is limited, and advertised focus or mood effects should not be treated as established clinical outcomes.

A growth-hormone-releasing-hormone analogue used in endocrine research and historically in some clinical settings.

An experimental small molecule described as an oestrogen-related-receptor agonist in preclinical metabolism and exercise-mimetic research.

A synthetic cosmetic peptide studied for effects on neurotransmitter-release machinery and the appearance of expression lines.

Elamipretide is a mitochondria-targeting peptide. The specific US medicine Forzinity received accelerated approval for Barth syndrome in patients weighing at least 30 kg; research-labelled SS-31 is not that authorised product.

An investigational dual glucagon and GLP-1 receptor agonist studied in obesity and metabolic liver disease.

A commercial research name generally associated with thymosin-beta-4-related material; exact sequence and composition should be analytically confirmed.

A short thymosin-beta-4-derived fragment used in laboratory research; it is not an approved medicine.

A parathyroid-hormone fragment used in authorised prescription medicines for osteoporosis and in bone-metabolism research.

A growth-hormone-releasing-factor analogue used in a specific approved indication in some countries and studied in metabolic research.

A thymic peptide preparation investigated in limited immune and ageing research; the catalogue name may represent a mixture rather than one defined molecule.

A thymic peptide investigated for immune-modulating effects and used clinically in some countries, but not universally authorised.

A dual GIP and GLP-1 receptor agonist associated with appetite, insulin and glucose-regulation pathways. Authorised prescription versions have established clinical uses, but unlicensed research material is not equivalent to an approved medicine.

A synthetic dipeptide investigated in limited studies of thymic, immune and gene-regulatory pathways.

A naturally occurring neuropeptide involved in vascular tone, smooth muscle, secretion and immune signalling.

A group of cobalamin compounds essential for DNA synthesis, blood-cell formation and neurological function; the exact form should be specified.

A supplier-defined blend of two experimental peptide materials. It is not an approved formulation and each component requires independent verification.

A catalogue combination of two distinct experimental materials discussed in preclinical tissue-repair research. Studies consider cell migration, inflammatory signalling and wound-repair pathways, but the combined ‘Wolverine’ format is not an approved clinical formulation.